Guardant Health Leads the Way in Blood-Based Single Cancer Screening
As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.
Too Old to Operate1d
Impact of Prophylactic Cranial Irradiation in Resected Early-Stage SCLC
The following is a summary of "Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers ...
Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial
Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...
Too Old to Operate9d
In Lung Cancer, Novel Preoperative Biomarkers Predict Recurrence Risk
Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...
Stories by SWNS on MSN10d
Strangers raise more than $150k for a man’s life saving cancer treatment
Strangers and friends have raised more than $150k for a man’s experimental life-saving cancer treatment after he found out ...
Hosted on MSN15d
Top 10 most common cancers in Rwanda
In Rwanda, cancer remains a leading health challenge, with breast, cervical, and prostate cancers being among the most prevalent. According to Dr. Theoneste Maniragaba, the Director of the Cancer ...
National Institute for Health and Care Excellence17d
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer
Chapter 2 of Appraisal and funding of cancer drugs from July 2016 (including the new Cancer Drugs Fund) – A new deal for patients, taxpayers and industry states that for those drugs with a draft ...
National Institute for Health and Care Excellence17d
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...
SciELO19d
Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma
The tumor-node-metastasis (TNM ... uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J Thorac Cardiovasc Surg 2007; 133: ...
Cancer Research UK19d
Lung cancer screening
Lung cancer screening aims to find lung cancer early. This is when there are more treatment options available and there is the best chance of treating it successfully. In the UK, the National ...
thorax.bmj19d
Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence
vghtpe.gov.tw Objective: Resection is the best treatment for patients with stage I non-small cell lung cancer (NSCLC). Patterns of disease recurrence after complete resection in stage I NSCLC have not ...
BMJ19d
Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis
Objectives To investigate the sex-specific association between smoking and lung cancer. Design Systematic review and meta-analysis. Data sources We searched PubMed and EMBASE from 1 January 1999 to 15 ...